Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

3.140 -0.120 (-3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,530,180
Open 3.310
Bid (Size) 3.150 (5)
Ask (Size) 3.170 (2)
Prev. Close 3.260
Today's Range 3.020 - 3.430
52wk Range 2.865 - 8.580
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Bluebird Bio Stock Is Sinking This Week
A potential regulatory delay is weighing on the biotech's stock this week. 
Via The Motley Fool
Analyst Ratings for bluebird bio
 
Via Benzinga

Performance

YTD
-54.76%
-54.76%
1 Month
-39.96%
-39.96%
3 Month
-52.35%
-52.35%
6 Month
-45.58%
-45.58%
1 Year
-39.62%
-39.62%

More News

Read More
bluebird bio Earnings Perspective: Return On Capital Employed
Via Benzinga
S&P 500 Up 1%; Bluebird Bio Shares Plummet
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Bluebird Bio Shares Are Plunging Today
Via Benzinga
bluebird bio Earnings Preview
Via Benzinga
Analyst Expectations for bluebird bio's Future
Via Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nasdaq Rises 1%; US Pending Home Sales Increase In February
Via Benzinga
UniFirst, Progress Software, SomaLogic And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
US Stocks Open Higher, Dow Jumps Over 200 Points
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
1 Beaten-Down Stock That Has a Lot to Prove in 2023
Via The Motley Fool
Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Via The Motley Fool
Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.